Gil Madre J, Lázaro Rodríguez S, Sentenac Merchán G, Sepúlveda Berrocal M A, Alises Moraleda J M, Cortés Bermejo S, García de Pedro J, Laín Teres N
Servicio de Urgencias, Hospital Virgen de la Salud, Toledo.
Rev Esp Cardiol. 1995 Jan;48(1):55-8.
There are multiple drugs options in the treatment of Paroxysmal Supraventricular Tachycardia (PST) after inefficacious vagal stimulus. In this study we compare two of these treatments: verapamil versus adenosin triphosphate (ATP).
Fifty patients with PST were randomly treated with either Verapamil (5 to 10 mg) or ATP (5 to 20 mg). The basal features of each group, and the efficacy and safety of the two drugs were compared. Verapamil failures were treated with ATP and vice versa.
The characteristics of both groups of treatment were similar. 86% of PST episodes were resolved with Verapamil use, versus 83% after ATP administration. Finally all patients were successfully treated with these drugs. No adverse effects were observed with Verapamil, whereas these effects were frequent with ATP use, but in any case requiring specific intervention.
Both Verapamil and aTP are an equally safe and effective treatment of PST, but transient and minor side effects are frequent after ATP administration.
在迷走神经刺激无效后，阵发性室上性心动过速（PST）的治疗有多种药物选择。在本研究中，我们比较其中两种治疗方法：维拉帕米与三磷酸腺苷（ATP）。
50例PST患者被随机给予维拉帕米（5至10毫克）或ATP（5至20毫克）治疗。比较每组的基线特征以及两种药物的疗效和安全性。维拉帕米治疗无效的患者用ATP治疗，反之亦然。
两组治疗的特征相似。使用维拉帕米后86%的PST发作得到缓解，使用ATP后为83%。最后所有患者均用这些药物成功治疗。使用维拉帕米未观察到不良反应，而使用ATP时这些反应较为常见，但在任何情况下均无需特殊干预。
维拉帕米和ATP对PST的治疗同样安全有效，但使用ATP后常出现短暂且轻微的副作用。
